Why was this work needed?
Clopidogrel is an anti-clotting drug which is recommended for people who have recently had a heart attack. However, it is difficult to know whether people continue to take this for the recommended length of time after they are discharged from hospital and, if they choose to stop taking it, what happens to them.
This research linked together three sets of data to try to understand more about what happens to people once they are discharged from hospital, after receiving treatment for a heart attack. It linked records of someone’s treatment and prescriptions in hospital with GP data showing what happened to them after discharge. They then linked these to national data recording individual deaths.
What were the benefits?
The research demonstrated that stopping taking clopidogrel is common, and that this is associated with an increased number of heart attacks and death. However, while the research demonstrated an association, it could not prove a causal link. Future research will continue to investigate this.
What type of data was involved?
This research linked data from four sources: Clinical Practice Research Datalink (CPRD), Hospital Episode Statistics (HES) Admitted Patient Care, Office for National Statistics (ONS) mortality and Myocardial Ischaemia National Audit Project (MINAP).
What was the legal basis for accessing the data?
The Health and Social Care Information Centre (now NHS Digital) carried out the linkage. After this, the records were de-personalised before being used by the researchers.
Who funded and collaborated on this work?
This study was funded by AstraZeneca UK Ltd. Researchers from CPRD, representatives from the MINAP data custodians, and cardiovascular healthcare professionals collaborated on this research.
Where can I go for more information?
- Page updated: 31 August 2017
- Print page